lundi 24 août 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· July 29, 2026

Dynatrace Appoints AI and Technology Leader Chandu Thota to its Board of Directors

View original at finance.yahoo.com
Dynatrace Appoints AI and Technology Leader Chandu Thota to its Board of Directors BOSTON, July 29, 2026--(BUSINESS WIRE)--Dynatrace (NYSE: DT), the leading AI-powered observability platform, today announced the appointment of Chandu Thota to its Board of Directors effective July 27, 2026…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Chandu Thota is honored to join the Dynatrace Board and believes Dynatrace has transformative potential similar to the products and platforms he has built, given its ability to deliver precise answers and intelligent automation as enterprises embrace AI at scale.

    60% confidence
  • Chandu Thota is a visionary technology leader whose experience leading AI product innovation and applied research will be invaluable to Dynatrace and will sharpen its strategy at the intersection of observability and AI.

    60% confidence

Cité dans ces articles de Via News

Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Notre lecture des données ›
Signaux que nous suivons
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Tendances que nous surveillons ›
Là où les sources divergent
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
Nous signalons les conflits ouvertement ›
Vérifié récemment
Vérifié avec la source d'origine
4,978
faits reliés à leur source — et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,978 faits vérifiés avec la source5,251 documents sources archivés
Interrogez ces données → isubstrate.com